Pacira BioSciences Inc. Common Stock (NASDAQ: PCRX)
45 Days left to seek lead plaintiff status.
The Complaint alleges that during the Class Period, Pacira disseminated materially false and misleading statements and/or concealed material adverse facts concerning the validity and scope of the Company's patents. On August 9, 2024, Pacira announced that the New Jersey District Court had invalidated its ‘495 patent. This announcement surprised investors and analysts alike as they reacted immediately to the revelations, and the price of Pacira’s common stock declined dramatically. Plaintiff seeks to recover damages that occurred as the result of Defendants' alleged violations of the federal securities laws.